Company News

Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry. Read more

Related stories

Read More

The Park community continues to grow with the arrival of the Internet Watch Foundation (IWF), a global leader in online ...

Read More

Mursla Bio is stepping up its expansion in the United States as it prepares to launch its liver cancer surveillance ...

Read More

Park member Gearset is featured in Business Weekly, with CEO Kevin Boyle reflecting on the company’s journey from startup to ...

Want to see your news featured here? Contact the team and let’s spread the word.